...
首页> 外文期刊>BMC Infectious Diseases >Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
【24h】

Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

机译:西班牙一群艾滋病毒感染者对潜伏性结核感染的资格和治疗结果

获取原文
           

摘要

Background Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion. Methods Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI). Results A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9). Conclusions A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.
机译:背景技术先前的研究已经证明了对人免疫缺陷病毒感染者进行潜伏性肺结核感染(TLTBI)的治疗效果,但很少有研究调查在合并感染人群中实施TLTBI的操作方面。用于TLTBI以及治疗处方,在一个HIV感染的西班牙队列中的开始和完成,并调查与治疗完成相关的因素。方法在2000年至2003年之间,在西班牙的10家基于HIV医院的诊所中对受试者进行了前瞻性鉴定。数据来自临床记录。使用比值比(OR)及其95%置信区间(95%CI)来测量关联。结果共招募了1242名受试者,对846名(68.1%)的TLTBI进行了评估。其中有181名(21.4%)符合TLTBI的资格,因为他们的结核菌素皮肤试验(TST)阳性(121)或因为他们的TST阴性/未知,但他们是结核病例的已知接触者或免疫力受损(60) 。在符合TLTBI资格的患者中,有122名(67.4%)发起的TLTBI:99名(81.1%)用异烟肼治疗了6、9或12个月; 23人(18.9%)的短期疗程包括利福平加异烟肼和/或吡嗪酰胺。总共有70例患者(57.4%)完成了治疗,39例(32.0%)违约,7例(5.7%)因不良反应而中断治疗,2例发展为TB,2例死亡和2例离开了治疗。与静脉注射药物相比,完成治疗与通过异性性行为感染艾滋病毒有关(OR:4.6; 95%CI:1.4-14.7)以及与利福平和吡嗪酰胺服用2个月相比,异烟肼治疗9个月(OR :8.3; 95%CI:2.7-24.9)。结论少数符合TLTBI资格的HIV感染患者实际上已经开始并完成了一个疗程。必须解决成功实施这种干预措施的障碍。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号